Narrative review explores evolving therapies for alopecia areata, highlighting safety and effectiveness issues.
New targeted therapeutic approaches (eg. biologics, small molecules) have significantly changed the management of inflammatory dermatology conditions in recent years. Alopecia areata (AA), a non-scarring autoimmune hair loss condition, is one of the latest diseases to benefit from these developments. Here we review traditional, new and evolving therapies for AA and highlight the benefits, challenges and uncertainties that come with these new options. We present various real-world data collection approaches currently available and introduce GRASS-UK/GRASS-International as a global collaborative network of prospective AA disease registers designed to study the longer-term safety and effectiveness of new AA therapies as they are introduced.
No takes yet. Share an insight, caveat, or question.
Khoda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: